IgM myeloma: A multicenter retrospective study of 134 patients
Jorge J. Castillo(Dana-Farber Cancer Institute), Morie A. Gertz(Medical University of South Carolina), Luděk Pour(University Hospital Brno), David Jayabalan(Cornell University), Elisabet E. Manasanch(National Institutes of Health), Elizabeth A. Morgan(Brigham and Women's Hospital), Mark A. Fiala(Washington University in St. Louis), Marion Eveillard(Nantes Université), Irene M. Ghobrial(Dana-Farber Cancer Institute), Anna Waszczuk‐Gajda(Medical University of Warsaw), Ravi Vij(Washington University in St. Louis), Ivan Špıčka(Charles University), Alessandro Gozzetti(University of Siena), Paul G. Richardson(Harvard University), Artur Jurczyszyn(Jagiellonian University), Jiří Jarkovský(Masaryk University), Hareth Nahi(Karolinska University Hospital), Jacob P. Laubach(Harvard University), Julio Dávila(Universidad de Salamanca), John L. Reagan(Vanderbilt University), Joshua Gustine(Boston University), Edvan de Queiroz Crusoé(Complexo Hospitalar Universitário Professor Edgard Santos), Lucie Brožová(Masaryk University), Rubén Niesvizky(Cornell University), Jacek Czepiel(Jagiellonian University), Vladimír Maisnar(Charles University), Barbara Lewicka(Jagiellonian University), Claudia E. Paba‐Prada(Harvard University), Roman Hájek(University Hospital Ostrava), Philippe Moreau(Centre National de la Recherche Scientifique), Vânia Hungria(Faculdade de Ciências Médicas da Santa Casa de São Paulo), Angela Dispenzieri(Mayo Clinic), Jatin J. Shah(The University of Texas MD Anderson Cancer Center), Tomáš Pika(University Hospital Olomouc)
Cited by 49
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k